跳至主要内容
临床试验/ITMCTR2000002936
ITMCTR2000002936尚未招募1 期

Efficacy evaluation of Fuzheng Jiedu Xiaoji decoction in the treatment of Hepatitis B - related advanced liver cancer and key components research

Beijing Ditan Hospital, Capital Medical University0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • (1) Meet the diagnostic criteria for hepatocellular carcinoma;
  • (2) Chronic hepatitis B virus infection;
  • (3) Patients with BCLC stage C and D;
  • (4) Men or women aged 18-65 years;
  • (5) TCM syndrome differentiation of deficiency of qi and yin, accumulation of poison stasis;
  • (6) Signing of informed consent.

排除标准

  • (1) Those who have a history of allergies to the applied Chinese medicine components;
  • (2) Overlapping hepatitis A, E or C and other hepatitis virus infections;
  • (3) Combining autoimmune hepatitis, drug-induced hepatitis, alcoholic liver disease, and various genetic metabolic liver diseases;
  • (4) Tuberculosis infection;
  • (5) HIV-infected patients;
  • (6) Patients with severe heart and kidney complications or other primary diseases;
  • (7) Patients with liver cancer metastasized from other tumors or patients with malignant tumors in other locations;
  • (8) Upper gastrointestinal bleeding;
  • (9) Hepatorenal syndrome;
  • (10) Pregnant or lactating women;
  • (11) People with mental illness who cannot cooperate; patients with a history of epilepsy and central nervous system disease.

研究者

相似试验